Shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating. AEterna Zentaris’ rating score has improved by 20% from three months ago as a result of a number of analysts’ upgrades and downgrades.

Brokers have set a 1 year consensus price objective of $7.25 for the company and are anticipating that the company will post ($0.85) earnings per share for the current quarter, according to Zacks. Zacks has also given AEterna Zentaris an industry rank of 68 out of 265 based on the ratings given to its competitors.

A number of equities research analysts have recently issued reports on AEZS shares. Maxim Group restated a “buy” rating and issued a $10.00 price target (down from $11.00) on shares of AEterna Zentaris in a research report on Thursday, November 10th. Zacks Investment Research lowered AEterna Zentaris from a “hold” rating to a “sell” rating in a research report on Tuesday, January 3rd. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of AEterna Zentaris in a research report on Sunday, November 20th. Finally, Canaccord Genuity restated a “buy” rating and issued a $7.50 price target (down from $9.00) on shares of AEterna Zentaris in a research report on Friday, November 11th.

ILLEGAL ACTIVITY NOTICE: This piece was first published by Daily Political and is owned by of Daily Political. If you are reading this piece on another site, it was illegally stolen and republished in violation of US & international copyright legislation. The legal version of this piece can be read at

AEterna Zentaris (NASDAQ:AEZS) traded up 5.71% during mid-day trading on Friday, hitting $2.59. The company had a trading volume of 80,404 shares. AEterna Zentaris has a 12 month low of $2.35 and a 12 month high of $5.59. The firm’s market capitalization is $30.23 million. The company has a 50-day moving average price of $3.60 and a 200 day moving average price of $3.59.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

5 Day Chart for NASDAQ:AEZS

Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for AEterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris Inc. and related companies with's FREE daily email newsletter.